^
BIOMARKER:

CD22 positive

i
Other names: CD22, CD22 Molecule, CD22 Antigen, SIGLEC2, Sialic Acid-Binding Ig-Like Lectin 2, B-Lymphocyte Cell Adhesion Molecule, T-Cell Surface Antigen Leu-14, B-Cell Receptor CD22, SIGLEC-2, BL-CAM, Sialic Acid Binding Ig-Like Lectin 2, Siglec-2
Entrez ID:
Related biomarkers:
Phase 1
Stanford University
Recruiting
Last update posted :
01/19/2022
Initiation :
09/12/2019
Primary completion :
09/01/2022
Completion :
09/01/2034
CD22
|
CD20 negative • CD22 positive
|
cyclophosphamide • fludarabine IV • CD22-CAR T-cell therapy
Phase 2
National Cancer Institute (NCI)
Recruiting
Last update posted :
01/17/2022
Initiation :
11/16/2018
Primary completion :
02/01/2022
Completion :
02/01/2022
ABL1 • BCR • CD19 • CD22
|
CD22 positive
|
Blincyto (blinatumomab) • Besponsa (inotuzumab ozogamicin)
Phase 3
Alliance for Clinical Trials in Oncology
Recruiting
Last update posted :
01/13/2022
Initiation :
06/01/2017
Primary completion :
03/01/2023
Completion :
08/01/2024
CD20 • CD22 • ITGB1
|
CD20 positive • CD22 positive
|
Rituxan (rituximab) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • vincristine • Besponsa (inotuzumab ozogamicin) • daunorubicin • Oncaspar liquid (pegaspargase) • mercaptopurine • thioguanine • allopurinol
Phase 4
Pfizer
Recruiting
Last update posted :
01/05/2022
Initiation :
07/01/2019
Primary completion :
09/14/2022
Completion :
09/22/2023
CD22
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
Phase 1
University of Virginia
Recruiting
Last update posted :
01/05/2022
Initiation :
03/22/2022
Primary completion :
01/30/2023
Completion :
11/30/2024
CD22
|
CD22 positive
|
cytarabine • prednisone • vincristine • methotrexate • Besponsa (inotuzumab ozogamicin) • daunorubicin • Oncaspar liquid (pegaspargase) • Otrexup (methotrexate)
Phase 1
University of Washington
Recruiting
Last update posted :
11/24/2021
Initiation :
09/24/2019
Primary completion :
02/28/2024
Completion :
02/28/2026
CD22
|
CD22 positive
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • prednisone • vincristine • Besponsa (inotuzumab ozogamicin) • daunorubicin • Solu-Cortef (hydrocortisone sodium succinate injection) • prednisone delayed-release tablet
Phase 1b/2
Roswell Park Cancer Institute
Recruiting
Last update posted :
10/29/2021
Initiation :
01/21/2021
Primary completion :
01/21/2023
Completion :
01/21/2024
CD22
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin) • Marqibo (vincristine liposomal)
Phase 1
Dana-Farber Cancer Institute
Recruiting
Last update posted :
10/20/2021
Initiation :
09/24/2021
Primary completion :
06/23/2023
Completion :
06/23/2026
CD22
|
CD22 positive
|
Venclexta (venetoclax) • Besponsa (inotuzumab ozogamicin) • Decadron (dexamethasone) • Maxidex (dexamethasone eye drops, suspension)
Phase 1
Shanghai General Hospital, Shanghai Jiao Tong U...
Recruiting
Last update posted :
09/29/2021
Initiation :
03/11/2019
Primary completion :
12/11/2021
Completion :
12/11/2021
CD19 • CD22
|
CD19 positive • CD22 positive
|
cyclophosphamide • fludarabine IV
Phase 1
Cellectis S.A.
Recruiting
Last update posted :
09/22/2021
Initiation :
10/14/2019
Primary completion :
10/14/2022
Completion :
10/14/2022
CD19 • CD22
|
CD22 positive
|
UCART22
Phase 1/2
Chongqing Precision Biotech Co., Ltd
Recruiting
Last update posted :
08/02/2021
Initiation :
05/23/2021
Primary completion :
01/01/2023
Completion :
07/01/2023
CD19 • IL6 • TNFA • CD22 • IL10
|
CD19 expression • CD22 positive
Phase 1
Southwest Oncology Group
Active, not recruiting
Last update posted :
07/19/2021
Initiation :
04/01/2014
Primary completion :
01/01/2022
Completion :
01/01/2023
CD4
|
CD22 positive
|
cyclophosphamide • prednisone • vincristine • Besponsa (inotuzumab ozogamicin)
Phase 1/2
Leland Metheny
Recruiting
Last update posted :
07/16/2021
Initiation :
07/31/2017
Primary completion :
11/01/2021
Completion :
06/01/2022
BCL2 • BCL6 • CD22
|
BCL6 rearrangement • BCL2 rearrangement • CD22 positive
|
Besponsa (inotuzumab ozogamicin)
Phase 1
Hebei Yanda Ludaopei Hospital
Recruiting
Last update posted :
06/07/2021
Initiation :
08/20/2020
Primary completion :
08/10/2022
Completion :
11/10/2022
CD19 • CD22
|
CD22 positive
|
fludarabine IV • YT-19/22
Phase 1
Stanford University
Recruiting
Last update posted :
05/05/2021
Initiation :
01/10/2020
Primary completion :
08/01/2025
Completion :
08/01/2035
CD19 • CD22
|
CD22 positive
|
cyclophosphamide • fludarabine IV • CD22-CAR T-cell therapy
Phase 1/2
Zhejiang University
Recruiting
Last update posted :
03/09/2021
Initiation :
03/05/2021
Primary completion :
03/05/2024
Completion :
03/05/2025
CD19 • CD22
|
CD22 positive
|
CD19/CD22 CAR-T cell therapy
Phase 1/2
Chongqing Precision Biotech Co., Ltd
Recruiting
Last update posted :
03/03/2021
Initiation :
08/25/2020
Primary completion :
12/30/2022
Completion :
07/01/2023
CD19 • IL6 • TNFA • CD22 • IL10
|
CD19 expression • CD22 positive
Phase 1/2
Affiliated Hospital to Academy of Military Medi...
Recruiting
Last update posted :
02/09/2021
Initiation :
08/20/2017
Primary completion :
08/20/2021
Completion :
08/20/2022
CD22
|
CD22 positive
Phase 1/2
Zhejiang University
Recruiting
Last update posted :
02/05/2021
Initiation :
01/31/2021
Primary completion :
01/31/2024
Completion :
01/31/2025
CD19 • CD22
|
CD22 positive
|
CD19 targeted CAR-T • CD19/CD22 CAR-T cell therapy
Phase 2
Beijing Boren Hospital
Recruiting
Last update posted :
01/28/2021
Initiation :
05/01/2020
Primary completion :
05/01/2022
Completion :
11/01/2022
ABL1 • CD19 • CD22
|
CD19 expression • CD22 positive
Phase 2
Beijing Boren Hospital
Recruiting
Last update posted :
01/28/2021
Initiation :
05/01/2020
Primary completion :
05/01/2022
Completion :
10/01/2022
ABL1 • CD22
|
CD22 positive
|
Anti-CD22 CAR-T Cells
Phase 1/2
Shanxi Province Cancer Hospital
Recruiting
Last update posted :
01/22/2021
Initiation :
01/15/2021
Primary completion :
12/31/2021
Completion :
12/31/2023
CD19 • IL6 • IFNG • TNFA • CD22 • IL2 • IL10
|
CD22 positive
|
cyclophosphamide
Phase 1/2
Shanxi Province Cancer Hospital
Recruiting
Last update posted :
01/20/2021
Initiation :
01/19/2021
Primary completion :
12/31/2021
Completion :
12/31/2023
CD19 • IL6 • IFNG • TNFA • CD22 • IL2 • IL10
|
CD22 positive
|
cyclophosphamide
Phase 1/2
Chongqing Precision Biotech Co., Ltd
Recruiting
Last update posted :
12/02/2020
Initiation :
09/01/2019
Primary completion :
12/30/2021
Completion :
07/01/2022
CD19 • IL6 • TNFA • CD22 • IL10
|
CD19 expression • CD22 positive
Phase 1
Bayer
Completed
Last update posted :
11/25/2020
Initiation :
11/20/2015
Primary completion :
11/11/2019
Completion :
11/26/2019
CD22
|
CD22 positive
|
epratuzumab-thorium-227 (BAY1862864)
Phase N/A
Hebei Senlang Biotechnology Inc., Ltd.
Recruiting
Last update posted :
09/14/2020
Initiation :
09/01/2020
Primary completion :
09/01/2022
Completion :
12/01/2022
IL6 • IFNG • TNFA • CD22 • IL10
|
CD22 positive
|
SENL-B19
Phase 1/2
M.D. Anderson Cancer Center
Not yet recruiting
Last update posted :
06/19/2020
Initiation :
11/30/2020
Primary completion :
08/31/2022
Completion :
08/31/2023
CD19 • CD22
|
CD22 positive
|
cyclophosphamide • fludarabine IV • CD19/CD22 CAR T-cells
Phase 1
Hebei Yanda Ludaopei Hospital
Not yet recruiting
Last update posted :
06/02/2020
Initiation :
06/01/2020
Primary completion :
12/01/2022
Completion :
12/01/2022
CD19 • CD22
|
CD20 negative • CD22 positive
|
GC022F • SENL-B19
Phase 1
Pfizer
Completed
Last update posted :
08/02/2019
Initiation :
03/01/2010
Primary completion :
07/01/2013
Completion :
03/01/2014
CD22
|
CD22 positive
|
cisplatin • Rituxan (rituximab) • gemcitabine • cyclophosphamide • prednisone • vincristine • Besponsa (inotuzumab ozogamicin) • dexamethasone
Phase 1
Pfizer
Completed
Last update posted :
03/15/2019
Initiation :
07/04/2008
Primary completion :
03/10/2010
Completion :
03/10/2010
CD20 • CD22
|
CD20 positive • CD22 positive
|
Rituxan (rituximab) • Besponsa (inotuzumab ozogamicin)
Phase 1
Pfizer
Completed
Last update posted :
12/17/2018
Initiation :
08/01/2003
Primary completion :
12/01/2010
Completion :
12/01/2010
CD22
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
Phase 1/2
Pfizer
Completed
Last update posted :
03/08/2018
Initiation :
05/04/2006
Primary completion :
05/19/2014
Completion :
06/02/2014
CD20 • CD22
|
CD20 positive • CD22 positive
|
Rituxan (rituximab) • Besponsa (inotuzumab ozogamicin)
Phase 2
Pfizer
Completed
Last update posted :
12/05/2017
Initiation :
06/08/2009
Primary completion :
10/31/2012
Completion :
10/31/2012
CD20 • CD22
|
CD20 positive • CD22 positive
|
Rituxan (rituximab) • Besponsa (inotuzumab ozogamicin)
Phase 2
Pfizer
Completed
Last update posted :
10/31/2017
Initiation :
07/30/2009
Primary completion :
01/10/2012
Completion :
06/27/2013
CD22
|
CD22 positive
|
Rituxan (rituximab) • Besponsa (inotuzumab ozogamicin)
Phase 1
MedImmune LLC
Completed
Last update posted :
10/02/2017
Initiation :
09/01/2008
Primary completion :
12/01/2014
Completion :
12/01/2014
CD22
|
CD22 positive
|
Lumoxiti (moxetumomab pasudotox)
Phase 1/2
Pfizer
Active, not recruiting
Last update posted :
04/13/2017
Initiation :
08/01/2011
Primary completion :
08/01/2014
Completion :
02/01/2016
CD22
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)
Phase 1
Xinqiao Hospital of Chongqing
Recruiting
Last update posted :
03/10/2017
Initiation :
03/01/2016
Primary completion :
12/01/2018
Completion :
12/01/2019
CD22
|
CD19 positive • CD22 positive
Phase 1/2
The Lymphoma Academic Research Organisation
Completed
Last update posted :
05/23/2016
Initiation :
12/01/2012
Primary completion :
08/01/2014
Completion :
03/01/2016
CD20 • CD22
|
CD20 positive • CD22 positive
|
Rituxan (rituximab) • gemcitabine • oxaliplatin • Besponsa (inotuzumab ozogamicin)
Phase 1
Wyeth is now a wholly owned subsidiary of Pfizer
Completed
Last update posted :
12/09/2015
Initiation :
03/01/2007
Primary completion :
07/01/2008
Completion :
07/01/2008
CD22
|
CD22 positive
|
Besponsa (inotuzumab ozogamicin)